Automated preparation of the dopamine D 2/3 receptor agonist ligand [ 11C]-(+)-PHNO for human PET imaging studies

Applied Radiation and Isotopes

Volumn 70, Issue 2, 2012, Pages 380-387

  Plisson, Christophe ^a   Huiban, Mickael ^a   Pampols Maso, Sabina ^a   Singleton, Görkem ^a   Hill, Samuel P ^a   Passchier, Jan ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Automation; Carbon 11; Dopamine D3; GMP; PHNO

Indexed keywords

CARBON-11; CLINICAL APPLICATION; DOPAMINE D3; GMP; HIGH QUALITY; PET IMAGING; PHNO; PLASMA CONCENTRATION; RECEPTOR LIGANDS; TESTING PROCESS;

AUTOMATION; LIGANDS;

BRAIN;

CARBON NAXAGOLIDE C 11; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG QUALITY; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RADIOCHEMISTRY;

AUTOMATION, LABORATORY; CARBON RADIOISOTOPES; DOPAMINE AGONISTS; HUMANS; ISOTOPE LABELING; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 81955164140     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2011.09.018     Document Type: Article

References (19)

1. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attuenation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9:762-767.
2. ICH guidelines, 2011. ICH Topic Q3C (R5) Impurities: Guideline for Residual Solvents. http://www.gmp-compliance.org/eca_news_2454_6816,6879,6874,6881,6975.html.
3. Gilbert J.G., Newman A.H., Eliot L., Gardner C.R., Ashby J.R., Heidbreder C.A., PAK A.C., PENG X.-Q., XI Z.-X. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 2005, 57:17-28.
4. Gross M.-L.P., Koch A., Mühlbauer B., Adamczak M., Ziebart H., Drescher K., Gross G., Berger I., Amann K.U., Ritz E. Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes. Lab. Invest. 2006, 86:262-274.
5. Heidbreder C.A., Andreoli M., Marcon C., Hutcheson D.M., Gardner E.L., Ashby C.R. Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict. Biol. 2007, 12:35-50.
6. Hilton J., Yokoi F., Dannals R.F., Ravert H.T., Szabo Z., Wong D.F. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl. Med. Biol. 2000, 27:627-630.
7. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 2000, 20:423-451.
8. Mizrahi R., Houle S., Vitcu I., Ng A., Wilson A.A. Side effects profile in humans of 11C-(+)-PHNO, a dopamine D2/3 agonist ligand for PET. J. Nucl. Med. 2010, 51:496-497.
9. Narendran R., Slifstein M., Guillin O., Hwang Y., Hwang D.-R., Scher E., Reeder S., Rabiner E., Laruelle M. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11c]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006, 60:485-495.
10. Passchier J., Gee A.D., Willemsen A., Vaalburg W., Van Waarde A. Measuring drug-related receptor occupancy with positron emission tomography. Methods 2002, 27:278-286.
11. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., Piccini P. Staging of serotonergic dysfunction in Parkinson's Disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 2010, 40:216-222.
12. Rabiner E.A., Slifstein M., Nobrega J., Plisson C., Huiban M., Raymond R., Diwan M., Wilson A.A., McCormick P., Gentille G., Gunn R.N., Laruelle M.A. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 2009, 63:782-793.
13. Reavill C., Taylor S.G., Wood M.D., Ashmeade T., Austin N.E., Avenell K.Y., Boyfield I., Branch C.L., Cilia J., Coldwell M.C., Hadley M.S., Hunter J., Jeffrey P., Jewitt F., Johnson C.N., Jones D.N.C., Medhurst A.D., Middlemiss D.N., Nash D.J., Riley G.J., Routledge C., Stemp G., Thewlis K.M., Trail B., Vong A.K.K., Hagan J.J. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294:1154-1165.
14. Searle G., Beaver J.D., Comley R.A., Bani M., Tziortzi A., Slifstein M., Mugnaini M., Griffante C., Wilson A.A., Merlo-Pich E., Houle S., Gunn R., Rabiner E.A., Laruelle M. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol. Psychiatry 2010, 68:392-399.
15. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 2006, 5:25-43.
16. Tziortzi A.C., Searle G.E., Tzimopoulou S., Salinas C., Beaver J.D., Jenkinson M., Laruelle M., Rabiner E.A., Gunn R.N. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. NeuroImage 2011, 54:264-277.
17. Vengeliene V., Leonardi-Essmann F., Perreau-Lenz S., Gebicke-Haerter P., Drescher K., Gross G., Spanagel R. The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J. 2006, 20:2223-2233.
18. Willeit M., Ginovart N., Kapur S., Houle S., Hussey D., Seeman P., Wilson A.A. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol. Psychiatry 2006, 59:389-394.
19. Wilson A.A., McCormick P., Kapur S., Willeit M., Garcia A., Hussey D., Houle S., Seeman P., Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 2005, 48:4153-4160.